Infliximab 3mg/kg intravenous infusion weeks 0, 2 and 6, then every 8 weeks (ensure DMARD co-prescribedweekly methotrexate preferred) Review at 3 months to assess response and further treatment (NB NICE Guidance states allow upto 6 months to assess effectiveness but earlier assessment considered more appropriate at WUTH) 
Full Response

Third line:
 Rituximab 1g iv infusion -2 doses given two weeks apart (co-prescribing of weekly methotrexate recommended) Review patient 6 months after infusion -further doses of rituximab should not normally be given at an interval less than every 6 months 3 and only in those patients who showed adequate initial response (DAS28 score reduced by >1.2)
Review at 3 months after changing to assess response and determine ongoing treatment. Adequate therapeutic trial is defined as: Treatment for at least 6 months, with at least 2 months at a standard target dose unless significant toxicity limits the dose tolerated. Treatment for less than 6 months where treatment was withdrawn because of drug intolerance or toxicity, but normally after at least 2 months at therapeutic doses.
